Navigation Links
BGI to play a pivotal role in demonstrating the superior performance of RNA-Seq
Date:11/2/2011

November 2nd, 2011, Shenzhen, China - BGI, the world's largest genomic organization, today announced its participation and pivotal role in demonstrating the superior performance of RNA-Seq in predicting patient outcomes as part of the Sequencing Quality Control (SEQC) Project launched by the U.S. Food and Drug Administration (FDA). The SEQC, also known as MAQC-III, is the third phase of the MicroArray Quality Control (MAQC), aimed at assessing the technical performance of next-generation sequencing (NGS) platforms for RNA and DNA analyses.

Microarrays were expected to be a primary source for pharmacogenomic and toxicogenomic data, but its progress has been hampered due to concerns on the lack of reproducibility and accuracy of the derived data. Recently, more and more scientists have been gradually conducting pharmaceutical and medical studies by utilizing NGS technology for advancing personalized nutrition and medicine. In late 2008, FDA turned its attention to sequencing technology and issued a statement calling for volunteers to participate in SEQC.

With the rapid development of NGS technology, RNA-Seq, also known as "Whole Transcriptome Shotgun Sequencing," is being adopted by the biomedical research community and FDA-regulated industries because of its potential for higher sensitivity in detecting low expression genes and greater specificity in distinguishing isoforms, among other advantages. To demonstrate the utility of RNA-Seq technology in predicting patient outcomes, the FDA, BGI and the University Children's Hospital of Cologne have been conducting together a study of cancer prognosis to assess the performance of RNA-Seq and microarrays using 500 neuroblastoma samples from MAQC-II.

In this project, BGI performs sequence library construction and sequencing as well as bioinformatics analysis for the massive amount of data being produced. "With our rich experience in RNA-Seq research, we believe we can make a significant contribution to the development of RNA-Seq technology and help accelerate its translation to clinical application," said Dr. Zhiyu Peng, Vice President of Research & Cooperation Division at BGI.

Dr. Matthias Fischer from the University Children's Hospital of Cologne stated, "While we have built predictive models for neuroblastoma patients with microarray data, some of those still need to be improved. Compared with microarray, the resulting massive RNA-Seq sequence data could be utilized to better understand human transcriptomics and identify functional genetic variants associated with disease and drug risks."


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Related biology news :

1. CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011
2. BGI to Play Pivotal Sampling, Next-Generation Sequencing and Bioinformatics Role in Earth Microbiome Project
3. Pivotal discoveries in age-related macular degeneration
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. Volcanoes played pivotal role in ancient ice age, mass extinction
6. SRNL demonstrating low-energy remediation with patented microbes
7. Seeking superior stem cells
8. Fat and healthy? York U study finds slim isnt always superior
9. AgriLife research: Multi-paddock grazing is superior to continuous grazing
10. Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management
11. First new C. difficile drug in a generation superior to existing treatments: Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... The global biotechnology services outsourcing market ... 2025, according to a new report by Grand ... of the function of outsourcing certain clinical and ... services outsourced, clinical trial management and contract manufacturing ... was the first pharmaceutical company to outsource its ...
(Date:1/18/2017)... to a new market research report "In situ Hybridization Market by Technique (FISH, ... Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by MarketsandMarkets, ... 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports Medicine ... Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long Island ... anterior cervical discectomy and fusion on a 42 year old female who was ...
(Date:1/18/2017)... PRUSSIA, PA (PRWEB) , ... January 18, 2017 ... ... clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt ... in engaging panel discussions to examine vital clinical research issues such as trial ...
Breaking Biology Technology: